Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Summary

This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate cancer.

Eligibility

Inclusion Criteria:

* GROUP 1 FOCUS GROUPS:

  * Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
* GROUP 1 SURVEYS:

  * Are 18 years of age or older
  * Have histologic evidence of prostate adenocarcinoma
  * Are requiring, have required, or will require prostate cancer treatment
  * Have an understanding of the protocol and its requirements
  * Are willing to fill in a questionnaire and participate in a focused interview
  * Are able and willing to sign an informed consent
* GROUP 1 INTERVIEWS:

  * Enrollment in the survey phase of the protocol
* GROUP 2:

  * Are 18 years of age or older
  * Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
  * Have histologic evidence of prostate adenocarcinoma
  * Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
  * Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
  * Have an understanding of the protocol and its requirements
  * Are able and willing to sign informed consent

Exclusion Criteria:

* GROUP 1 FOCUS GROUPS:

  * Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
* GROUP 1 SURVEYS:

  * Do not identify as Black men
  * Have not been diagnosed with prostate cancer
* GROUP 1 INTERVIEWS:

  * Not enrolled in the survey phase of the protocol
* GROUP 2:

  * Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
  * Have not been diagnosed with histologic evidence of prostate adenocarcinoma
  * Are not requiring active standard anti-cancer therapy

Conditions2

Locations1 site

Browse More Trials